TrialBMC infectious diseases2025

A randomized, non-inferiority phase III clinical trial of immunogenicity and safety of 5-dose and 4-dose schedules of a freeze-dried human rabies vaccine (MRC-5 cells) in participants aged 10-60.

Danhua Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.